BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 11807679)

  • 1. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
    Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
    Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
    Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
    Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.
    Jain LR; Denning DW
    J Infect; 2006 May; 52(5):e133-7. PubMed ID: 16427702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
    Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
    Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience with voriconazole in invasive aspergillosis].
    Thiel E; Schwartz S
    Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole-associated myositis.
    Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
    J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
    Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
    Mattner F; Chaberny IF; Weissbrodt H; Fischer S; Gastmeier P; Haubitz B; Gottlieb J; Mattner L; Strueber M
    Mycoses; 2005; 48 Suppl 1():51-5. PubMed ID: 15826288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
    Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
    Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
    Cordonnier C; Maury S; Pautas C; Bastié JN; Chehata S; Castaigne S; Kuentz M; Bretagne S; Ribaud P
    Bone Marrow Transplant; 2004 May; 33(9):943-8. PubMed ID: 15034546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.